Memories associated with drug use increase vulnerability to relapse in substance use disorder (SUD), and there are no pharmacotherapies for the prevention of relapse. Previously, we reported a promising finding that storage of memories associated with methamphetamine (METH), but not memories for fear or food reward, is vulnerable to disruption by actin depolymerization in the basolateral amygdala complex (BLC). However, actin is not a viable therapeutic target because of its numerous functions throughout the body. Here we report the discovery of a viable therapeutic target, nonmuscle myosin IIB (NMIIB), a molecular motor that supports memory by directly driving synaptic actin polymerization. A single intra-BLC treatment with Blebbistatin (Blebb), a small-molecule inhibitor of class II myosin isoforms, including NMIIB, produced a long-lasting disruption of context-induced drug seeking (at least 30 days). Further, postconsolidation genetic knockdown of Myh10, the heavy chain of the most highly expressed NMII in the BLC, was sufficient to produce METH-associated memory loss. Blebb was found to be highly brain penetrant. A single systemic injection of the compound selectively disrupted the storage of METH-associated memory and reversed the accompanying increase in BLC spine density. This effect was specific to METH-associated memory, as it had no effect on an auditory fear memory. The effect was also independent of retrieval, as METH-associated memory was disrupted 24 h after a single systemic injection of Blebb delivered in the home cage. Together, these results argue for the further development of small-molecule inhibitors of NMII as potential therapeutics for the prevention of SUD relapse triggered by drug associations.
INTRODUCTION
Substance use disorder (SUD) is a chronic, relapsing disorder. Thus a major challenge facing the treatment of SUD is preventing relapse after patterns of drug-seeking behavior have become deeply engrained. During drug use, a multitude of associations form between the drug and stimuli present at the time, which can range from drug paraphernalia to components of the environment in which the drug is used. 1 The associations become highly motivating on their own such that they can serve as rapid, conscious or unconscious triggers to seek out the drug. Perhaps most troubling, these drug-associated stimuli can retain their ability to motivate drug-seeking behavior, even after seemingly successful rehabilitation and prolonged drug-free periods.
Pharmacotherapeutic options for SUD are extremely limited. A few, moderately effective replacement therapies exist for opiate, nicotine and alcohol dependence. However, no such options exist for psychostimulant dependence, and further, there are no pharmacotherapies for the prevention of relapse associated with any drug of abuse. Current behavioral modification strategies commonly employ exposure therapy, a form of memory extinction that targets each trigger by accelerating learning of a new, nonreward contingency for each associated stimulus. 2 Research efforts are directed at identifying molecular accelerators of extinction to increase the speed and efficacy of exposure therapy. [3] [4] [5] [6] [7] [8] However, because exposure therapy leaves the original drug-associated memory intact, the therapeutic efficacy of this approach is limited by the constant potential for spontaneous renewal of the conditioned drug-seeking response. A strategy being developed to more permanently alter drug-associated memories takes advantage of reconsolidation, a short period of time following retrieval when a memory is susceptible to disruption. [9] [10] [11] [12] [13] [14] However, the triggers for drug-associated memories can be numerous for an individual and often unconscious or abstract, 15 suggesting that the retrieval-based strategies of extinction and reconsolidation may have limited efficacy. An alternative approach might be one that does not rely on retrieval instead of targeting drug-associated memories while in storage. However, in the absence of retrieval, this poses a new challenge of how to selectively target SUD associations without disrupting the countless other memories that have accumulated throughout life. Recently, we identified an actin-based mechanism employed by the brain to store memories associated with the psychostimulant methamphetamine (METH). 16 Dendritic spines, the small, but highly dynamic postsynaptic structures found at the majority of forebrain excitatory synapses, are thought to be the structural site of memory storage. 17 At the time of memory formation, dendritic spines facilitate signal integration and information storage by enabling input-specific biochemical and electrical isolation of synapses. Furthermore, volumetric and functional changes of dendritic spines are critical for the successful formation of long-term memories. 18, 19 The workhorse of this structural and functional plasticity is actin polymerization, the process of linking actin monomers (G-actin) into complex, branched filaments (F-actin). 20, 21 These actin filaments comprise the cytoskeleton in dendritic spines and are surprisingly dynamic, capable of making rapid structural changes on the order of seconds. [22] [23] [24] [25] [26] Indeed, disrupting learning-induced F-actin dynamics at the time of training prevents the formation of long-term fear memories. 25, [27] [28] [29] [30] Findings from synaptic plasticity and fear memory studies indicate that F-actin dynamics are under tight temporal control, such that actin rapidly stabilizes after synaptic stimulation. This renders the cytoskeleton and associated synaptic potentiation and memory invulnerable to disruption by actin-depolymerizing agents, such as Latrunculin A, within minutes of stimulation. 22, 29, 30 However, recent evidence from our laboratory suggests that the F-actin supporting METH-associated memories remains dynamic long after learning, presenting an unanticipated weakness of these pathogenic associations. 16 Indeed, METH-associated memories can be selectively disrupted through actin depolymerization in a subregion of the amygdala, the brain's emotional memory center, long after learning has occurred and in the absence of retrieval. Importantly, the same manipulation has no effect on associative memories for fear or food reward. Further, METH-associated memory is accompanied by an increase in spine density in the basolateral amygdala complex (BLC) that is reversed by actin depolymerization, corresponding to loss of the memory.
Given these results, actin depolymerization would seem to be a promising therapeutic target, particularly given that a single treatment with Latrunculin A is sufficient to immediately disrupt METH-associated memories. However, β-actin, the isoform implicated in adult neuronal structural plasticity, is ubiquitously expressed throughout the body and is critical for a multitude of processes, such as cell polarity, adhesion and migration. Because of the limitations associated with actin depolymerization as a therapeutic, we have turned our efforts toward identification of upstream regulators of the synaptic actin cytoskeleton in the hopes of identifying a viable therapeutic target for the selective disruption of METH-associated memory. These efforts have led to the myosin family, which is comprised of 143 molecular motors spread over 17 different classes, each with tissue-specific properties. 31 We focused our investigation on nonmuscle myosin II (NMII), a myosin subclass and ATP-dependent molecular motor we have previously demonstrated to have a crucial, temporally restricted role in synaptic actin polymerization and fear memory. 25, 30 
MATERIALS AND METHODS
All procedures were performed in accordance with the Scripps Research Institute Animal Care and Use Committee and national regulations and policies.
Drugs
Methamphetamine hydrochloride (Sigma-Aldrich, St Louis, MO, USA) was delivered intravenously at 0.02 mg in a 0.05 ml infusion to rats for self-administration and intraperitoneally (IP) at 1.0 mg kg − 1 to rats or 2.0 mg kg − 1 to mice for conditioned place preference (CPP). Both enantiomers of Blebbistatin (Blebb; − = active Blebb, + = inactive Blebb (Vehicle control); Calbiochem, Billerica, MA, USA) were infused into the BLC at a concentration of 90 ng μl − 1 in 10% dimethyl sulfoxide (DMSO) and 0.9% saline. To address poor solubility of active (− ) Blebb, racemic (+/ − ) Blebb (Tocris, Bristol, UK) was used for IP injections. It was diluted to 1 mg ml −1 in a vehicle of 0.9% saline and 6.7% DMSO/25% Hydroxypropyl β-Cyclodextrin and delivered to mice at 10 mg kg − 1 . Intra-BLC infusions were delivered at a rate of 0.25 μl min − 1 over 2 min for rats and 0.15 μl min − 1 over 2 min for mice. Infusers were left in place for 1 min to allow for diffusion of the drug away from the needle tip. At the completion of behavioral procedures, 40-μm sections were stained with cresyl violet to verify placement of the infusion needle tips within the BLC (Supplementary Figure S1) .
Pharmacokinetics See Supplementary Information

Behavioral procedures
Self-administration. There were four different phases of self-administration: food training, METH training, extinction, and reinstatement. Prior to catheter/guide cannula implantation and the start of self-administration training, all rats underwent food training. METH self-administration training was conducted during 2-h sessions for 14 consecutive days in Context A. Animals were trained to press the active lever on a Fixed Ratio schedule of 1 (FR1) for METH reinforcement, followed by a 20-s time-out period. Lever presses on the inactive lever were not reinforced. Animals moved on to the extinction phase after achieving a minimum average of 10 METH infusions per day over 14 consecutive days. Extinction training consisted of 2-h sessions free of reinforcement conducted in Context B. Animals were assigned to a different operant chamber during extinction. Reinstatement testing took place in Context A for 1 h, starting 24 h after the last day of extinction. Animals underwent three reinstatement tests: 1 day (R1), 2 days (R2), and 30 days (R30) following extinction. Thirty minutes prior to reinstatement day 1 (R1), animals received one intra-BLC infusion of (− ) Blebb or (+) Blebb (vehicle control).
Conditioned place preference. CPP was performed as previously described. 16, 32, 33 For mice, the protocol consisted of three phases: pretesting, training, and testing. Pretesting took place over 2 days, during which mice were allowed to freely explore the CPP apparatus for 30 min each day. The first 30-min session and the first 15 min of the second session served as a habituation period to allow the mice to acclimate to the novel context without inducing latent inhibition, while the final 15-min period was used to assess predrug compartment preference. Mice were trained over 4 consecutive days with twice daily training sessions, such that mice received both METH (2 mg kg −1 ) and saline each day. Randomization was performed such that starting chamber, initial preference and time of day for METH treatment were counterbalanced within groups. Further, each mouse cage was counterbalanced between the control and treatment groups. Testing consisted of 15 min free access to the CPP apparatus and was conducted at least 2 days after the final day of training. See Supplementary Information for additional details regarding rat CPP.
Fear conditioning. Modified mouse Noldus Phenotypers were used for auditory fear conditioning. Mice were first habituated to the training context for a total of 12 min over three exposures in 1 day. For training, mice explored the chamber for 3 min before receiving three pairings of a 30-s auditory tone (6 kHz, 85 dB) that coterminated with a foot shock (1 s, 0.5 mA). For testing, mice explored the novel test context for 3 min, 48 h after training, followed by three 30-s presentations of the tone with a 30-s inter-trial interval. Freezing behavior was assessed during each 30-s tone presentation and averaged across the three tones.
See Supplementary Information for additional behavioral procedure details.
RNA sequencing RNA-Seq was performed on tissue isolated from 8-to 12-week-old naive male mice. RNA was extracted from the BLC with the miRVANA PARIS RNA Kit (Life Technologies, Carlsbad, CA, USA), and 100 ng from each sample (n = 4) was used for library preparation with the TruSeq RNA Sample Prep Kit (Illumina, San Diego, CA, USA). Library preparation and 150-bp pairedend sequencing on the Illumina NextSeq 500 were performed by the Scripps Florida Genomics Core. Reads were mapped to the genome using the TopHat/Bowtie software 34, 35 and normalized means were obtained using the DeSeq package 36 in Bioconductor. RPKM (reads per kilobase of exon per million reads mapped) values were used to determine basal levels of myosin II heavy chains.
Short hairpin RNA (shRNA)-and small interfering RNA (siRNA)-mediated focal knockdown of Myh10 (NMIIB) from the skull) at a rate of 0.13 μl min − 1 using an automated injection pump through a 10-μl syringe and 33-gauge stainless steel needle (Hamilton, Reno, NV, USA). Tissue was collected 72 h after testing to confirm MYH10 knockdown. See prior publications for additional details on viruses and images of injection site. 9, 18, 23 Knockdown of Myh10 with siRNA was first assayed in naive mice 24 h after intra-BLC injection of the appropriate siRNA pool (ON-TARGETplus SMARTpool, mouse Myh10 or nontargeting pool; Dharmacon, Waltham, MD, USA; see Supplementary Table S1 for target sequences) using JetSI transfection reagent (Polyplus Transfection, Illkrich, France). 33, [37] [38] [39] The appropriate siRNA-JetSI complexes were injected bilaterally into the BLC (AP: 1.5 mm, ML: ± 3.2 mm from bregma and DV: -4.7 mm from the skull) at 1 μl at 200 nl min − 1 in the same way that shRNA-AAVs were injected. In a separate group of mice used for behavioral testing, Myh10 or control siRNAs were infused into the BLC through bilateral guide cannulae after training, as described above. For additional details regarding confirmation of knockdown, see Supplementary Information. 
Statistical analysis
Wilcoxon signed rank tests were used to assess CPP compartment preferences. 32, [40] [41] [42] [43] [44] One-way analysis of variance (ANOVA) and repeatedmeasures ANOVAs were used for all other experiments, with Tukey's post hoc tests when appropriate. Shapiro-Wilks normality test and Levene test were used to verify that all data sets met the criteria for normal distribution and equal variance, respectively. Statistical significance was set at P ⩽ 0.05, and variation is presented as s.e.m.
RESULTS
Inhibition of amygdalar myosin II produces a long-lasting disruption of context-induced drug seeking
We recently demonstrated that intra-BLC Blebb, a small-molecule inhibitor of class II myosin isoforms, including NMIIs, 45 disrupted METH CPP. 16 Therefore, we first sought to address the potential for Blebb to produce a long-lasting disruption of drug seeking by using a gold standard model of memory-induced drug seeking, context-induced reinstatement of instrumental lever pressing for METH. [46] [47] [48] [49] Re-exposure to the METH-paired context reinstated drug seeking in controls but not those that received Blebb infusions targeted at the BLC prior to testing (R1 Active Lever: F (1,12) = 8.49, P o0.05). As with Latrunculin A, 16 inhibiting myosin II also prevented METH seeking in a subsequent Blebb-free test session 24 h later (Figure 1c ; R2 Active Lever: F (1,12) = 4.83, P o0.05). Furthermore, the single Blebb infusion prior to Reinstatement Test 1, produced a long-lasting disruption of drug seeking, such that lever pressing was still attenuated at a third reinstatement test 30 days later (Figure 1c ; R30 Active Lever: F (1,12) = 23.49, P o 0.0005). This longlasting effect indicates that spontaneous recovery of the memory did not occur.
The NMIIB isoform is required to maintain a METH-associated memory Several different myosins are expressed in the brain, including members of the myosin II class. In addition to NMIIs, Blebb inhibits skeletal, cardiac and some smooth muscle myosin IIs. 45, [50] [51] [52] Baseline gene expression analysis by RNA sequencing indicates that no skeletal muscle isoforms of myosin II are present in the BLC of adult mice. However, the genes encoding the heavy chains of two of the cardiac muscle myosin IIs, Myh7 and Myh7b, are expressed, along with the smooth muscle myosin heavy chain (Myh11) and all three NMII isoforms, Myh9 (NMIIA), Myh10 (NMIIB) and Myh14 (NMIIC), with Myh10 being the most highly expressed (F (5,18) = 47.44, P o 0.0001; Figure 2a ). Proteomic analyses have indicated that all five of these myosin II heavy chains are expressed at the synapse, and we have previously reported that cardiac Myh7b, while expressed at very low levels in the brain, is capable of regulating hippocampal dendritic spine synapse structure and function. [53] [54] [55] Therefore, while our previous findings related to fear memory formation suggest the current effects of Blebb on METH-associated memory are likely mediated through the most abundant myosin II, NMIIB (Myh10), 25, 30 we cannot be certain whether a specific myosin II isoform is responsible.
To address this, we first used an rAAV vector expressing an shRNA targeting Myh10 to determine whether the specific NMII isoform, NMIIB, supports a METH-associated memory in the BLC (Figure 2b) . 25 Importantly, there were no differences between control and Myh10 shRNA animals in pretraining preference for neither CPP compartment in terms of time spent in the black vs white side (Figure 2c ; RM-ANOVA, F (1,18) = 0.16, P40.05), consistent with an 'unbiased' protocol, nor was there a difference once the animals had been randomly assigned so that an equal number had the conditioned stimulus (CS+) paired with the black side, as with the white. Thus all animals received METH in their least pretraining preferred compartment to avoid introducing any potential bias to posttraining preference (CS+ Control shRNA: 330.3 ± 10.6 s, Myh10 shRNA: 333.7 ± 11.8 s; CS − Control shRNA: 380.9 ± 10.5 s, Myh10 shRNA: 385.5 ± 20.0 s; RM-ANOVA, F (1,18) = 0.16, P40.05). Further, locomotion was equivalent between groups during the Pretest when initial preference was established and during the posttraining test (see Supplementary Table S2) . Animals treated with the control shRNA displayed a robust METHassociated memory at testing, preferring the drug-paired context (CS+) over the saline-paired context (CS − ), whereas animals treated with the Myh10 shRNA showed no evidence of a preference (Figure 2d ; Control shRNA: z = − 2.67, P o 0.05; MyH10 shRNA z = − 0.051, P40.05). In subsequent tissue analysis, we confirmed that MYH10 protein levels were significantly reduced in the BLC of rats injected with the Myh10 shRNA (Figure 2e:  F (1,18) = 5.0, P o0.05), without affecting mRNA levels of the closely associated NMIIA and NMIIC heavy chains, Myh9 (F (1,8) = 0.107, P40.05) and Myh14 (F (1, 8) = 0.991, P40.05; Figure 2f ). These results indicate that NMIIB is required for METH-associated memory. However, this does not address NMIIB's contribution to the specific phase of memory storage.
To more precisely examine the contribution of NMIIB to the maintenance of a METH-associated memory, we used siRNAmediated acute focal knockdown of Myh10 in the BLC. Using naive adult mice, we first confirmed effective knockdown of MYH10 protein in vivo 24 h after intra-BLC siRNA injection, as compared with a nontargeting control siRNA (Figure 3a , P o 0.005). Interestingly, MYH10 levels had already begun to recover to baseline levels by 48 h post-siRNA injection, indicating a rapid turnover rate for Myh10 (Figure 3a) . To achieve the necessary temporal control over MYH10, the appropriate siRNA pool was infused into the BLC 1 day after the final training session, and METH-associated memory was assessed 24 h later (Figures 3b and c) , a time point at which the NMII heavy chain was significantly knocked down ( Figure 3a) . Mice that received intra-BLC infusions of the nontargeting control siRNA showed a robust preference for the drug-paired compartment. However, mice that received the MyH10 siRNA demonstrated no such preference (Figure 3c ; Overall: F (1,24) = 9.36, P o0.005; Control vs Myh10 T1: F (1,24) = 11.82, P o0.005). This effect persisted into a subsequent test 24 h later, despite the rapid recovery rate of MYH10 from siRNAmediated knockdown (F (1,24) = 3.95, P ⩽ 0.05; Figure 3a ). This latter finding is consistent with results obtained with Blebb, pointing to the acute nature of NMIIB inhibition's ability to produce a persistent METH-associated memory disruption. And again, as with the Myh10-AAV, no differences in locomotion were present between the experimental and control groups (Supplementary  Table S2 ). Further, there was no effect of the Myh10 siRNA on Myh9 (F (1,3) = 0.98, P40.05) or Myh14 mRNA levels (F (1,3) = 0.236, P40.05; Figure 3d ).
METH-associated memory storage can be selectively targeted from the periphery with a myosin II inhibitor The Topological Polar Surface Area (TPSA), an in silico calculation of the molecular surface area of all polar atoms, 56 of Blebb is reported in PubChem to be 52.9 A 2 . Generally, compounds with a TPSA o 90 A 2 are expected to have high brain penetrance. 57 Therefore, given the therapeutic potential of a systemic drug delivery option for SUD relapse, we investigated the ability of systemically administered Blebb to cross the blood-brain barrier and disrupt METH-associated memory.
As an initial in vivo screen, we assessed the effect of a single IP injection of Blebb on tissue distribution and several measures of health in mice. Unfortunately, solubility issues precluded the use of the pure active enantiomer of Blebb. Indeed, a thermodynamic solubility test confirmed this issue, with a noticeable precipitate observed with the pure enantiomer, but not racemate, immediately upon addition of DMSO stock. The final concentration after 24 h was 315 μM for the pure enantiomer and 924 μM for the racemate. Thus racemic Blebb was used at 10 mg kg − 1 , delivering 5 mg kg − 1 of the active enantiomer. Tissue was collected 15 and 45 min after IP injection. As anticipated, there was an excellent brain penetrance, as determined by the brain-to-plasma ratio (Supplementary Table S3 ). Acute effects of the compound were monitored in a separate group of mice for 2 h post-IP injection. Blebb had no apparent effects on any of the health measures (Supplementary Table S4 ), which were selected and ratings developed based on previously published methods for phenotyping mice after pharmacological and genetic manipulations. 58 In a parallel set of experiments, microsomal stability and in vivo pharmacokinetic properties of Blebb were determined by intravenous injection of the pure active enantiomer (1 mg kg − 1 ) and plasma collection at several time points over 8 h postinjection. Blebb displayed poor microsomal stability, particularly in rat and mouse (Supplementary Table S5 ). Further, Blebb was rapidly cleared from plasma, with undetectable levels by 60 min postinjection (Supplementary Table S5 ). Shortly after intravenous injection, a sharp decline in motor function was noticed and maintained for the first 30 min. Full recovery was seen by 60 min postinjection, presumably when the drug had cleared. This was unexpected, as mice given 10 mg kg − 1 of racemic Blebb showed normal behaviors during the same postinjection time frame (Supplementary Table S4 ), including normal locomotion during the first 30 min (Distance-Veh: 12973.98 ± 877.1 cm, Blebb: 11936.55 ± 1930.5 cm, P = 0.64; Velocity-Veh: 7.39 ± 0.50 cm s − 1 , Blebb: 6.76 ± 1.05 cm s − 1 , P = 0.61). These results indicate a narrow therapeutic index for Blebb, perhaps owing to its actions on cardiac myosin IIs. Further, it suggests that only a strikingly brief window of myosin II inhibition may be necessary to produce a lasting disruption of METH-associated memory. Additional experiments will be needed to determine the rate of clearance from the brain.
Using the same dose and route of administration as was used to assess the health effects and brain penetrance of Blebb, we determined the impact of systemically administered Blebb on a consolidated METH-associated memory. Two days after the final METH CPP training session, a single IP injection of Blebb was administered 30 min prior to assessment of METH-associated memory in the absence of METH reinforcement (Figure 4a ). Vehicle-treated controls displayed a strong METH-associated memory, preferring the previously drug-paired context (CS+) over the saline-paired context (CS − ) (Figure 4b ; z = − 2.16, Po 0.05). However, similar to intra-BLC LatA and Blebb in rats, 16 systemic Blebb-treated mice displayed an immediate memory disruption (Figure 4b ; z = − 0.79, P40.05), with no effect on locomotion (Supplementary Table S2) .
METH-associated memory is accompanied by an increase in BLC spine density that is reversed by an intra-BLC infusion of Latrunculin A. 16 Importantly, Latrunculin A has no effect on spine density in control, saline-treated mice. 16 Therefore, we next sought to determine whether the memory-disrupting effects of systemic Blebb were accompanied by a similar decrease in BLC spine density. Following the behavioral testing depicted in Figure 4b , the BLC of these vehicle or Blebb-treated Thy1-GFP (m) mice was imaged and spine density was determined (Figure 4c ). Thy1-GFP(m) mice express enhanced GFP in the forebrain pyramidal neurons with clear labeling in the BLC. 16, 59 All dendrites chosen for spine density analysis were comparable in width across groups (F (1,10) = 1.22, P40.05). METH-associated memory loss induced by systemic myosin II inhibition was accompanied by a significant reduction in BLC spine density compared with control METH CPP animals that received vehicle infusions prior to testing (Figure 4c ; F (1,10) = 4.8, P o0.05). The effect size was strikingly similar to that of Latrunculin A. 16 Pretraining intra-BLC Blebb disrupts the formation of an auditory fear memory. However, when given prior to testing, this same drug treatment has no effect on auditory or contextual fear memories. 25, 29, 30 Therefore, we next addressed the selectivity of systemic Blebb for a drug-associated memory by assessing the effects on fear memory. Systemic Blebb had no effect on the expression of a previously consolidated, BLC-dependent auditory fear memory (Figures 4d and e; F (1,24) = 1.61, P40.05) or spine density (Figure 4f ; F (1, 8) = 0.17, P40.05), which is increased in the BLC with fear memory. 60, 61 All dendrites chosen for spine density analysis were comparable in width across groups (F (1, 8) = 1.99, P40.05). Taken together, these results indicate that Blebb is able to cross the blood-brain barrier at a high enough concentration to inhibit myosin II and alter METH-associated memory (Figure 4b ) and spine density (Figure 4c ), while leaving fear memory and fear memory-associated spines intact (Figures 4e and f) .
A therapeutic advantage of targeting the actin cytoskeleton is that its effect on METH-associated memory does not depend upon retrieval. To determine whether myosin II inhibition is capable of disrupting the storage of a METH-associated memory in the absence of retrieval, mice received a single systemic injection of Blebb in the home cage 2 days after the completion of training (Figure 5a ). Twenty-four hours later, Blebb-treated mice displayed no METH-associated memory (Figure 5b ; Vehicle: z = − 2.20, Po 0.05; IP Blebb: z = 0.0, P40.05). Two weeks later, the same animals were trained for auditory fear conditioning and tested the following day in the absence of any drug treatment (Figure 5a ). Animals that previously underwent an IP Blebb-induced disruption of METH-associated memory expressed an auditory fear memory equal in strength to previously vehicle-treated controls (Figure 5c ; F (1, 13) = 0.28, P40.05), indicating that prior Blebb treatment did not disrupt the brain's ability to form future memories.
DISCUSSION
In a prior study, we discovered that the storage of METHassociated memories appears to be governed by a unique state of continuously cycling actin, 16 unlike other types of amygdaladependent memories that are supported by an actin cytoskeleton that stabilizes within minutes of learning. 25, 30 Unfortunately, the therapeutic potential of this finding was limited because direct targeting of actin polymerization via peripheral drug administration would have lethal side effects. Indeed, many toxins found in nature potently target actin-based cytoskeletal dynamics. Here we report a critical advance by identifying a viable target for achieving actin depolymerization, NMIIB, to serve as the foundation for future neurotherapeutic development. Indeed, systemic delivery of the myosin II inhibitor, Blebbistatin, reliably and selectively disrupted the storage of METH-associated memory and associated structural plasticity. Myosin II's canonical function is to drive retrograde actin flow in growth cones of developing neurons by imparting a shearing force on them. 62 If myosin II function is lost, the flow of actin stops, and the growth cone collapses. Additionally, we have previously demonstrated that the NMIIB isoform participates in structural reorganization of the spine actin cytoskeleton in response to synaptic stimulation by applying a similar mechanical force to drive F-actin polymerization. 25 This reorganization is rapid, complete within minutes of stimulation and supports the stable expression of long-term potentiation, as well as hippocampus and amygdala-dependent fear memories. 25, 30 Contrary to its role in these more traditional forms of plasticity and memory, our current study suggests that NMIIB remains constitutively active in support of METH associations, continuing to drive actin polymerization, such that memories associated with METH can be selectively targeted without the need for retrieval days to weeks after learning.
Immediately following withdrawal, most substance users enter a 'honeymoon' phase where they report feeling physically and emotionally well, with few cravings. 63 However, approximately 1-3 months into recovery, many abstinent individuals report hitting a 'wall'. This phase of recovery is marked by anhedonia and strong cravings that often result in relapse. 63 A comparable pattern of behavior, termed the incubation of craving, has been observed in animal self-administration models where motivation to drug seek can increase over the course of 30 days of forced abstinence. [64] [65] [66] Time-dependent adaptations of nucleus accumbens glutamatergic synapses are known to partially mediate this effect, and recent evidence indicates that this is modulated by silent synapses on glutamatergic projections from the amygdala and prefrontal cortex. [67] [68] [69] Indeed, despite the extinction effects of repeated reinstatement testing in the current study, the animals treated with the inactive enantiomer of Blebb (Vehicle; Figure 1 ) showed no sign of reduced drug seeking from the first (R1) to the final reinstatement (R30) sessions, suggesting a powerful drive to seek METH more than a month after drug cessation. Animals given a single treatment with the active enantiomer of Blebb (Blebb; Figure 1 ), on the other hand, showed no sign of spontaneous recovery of the drug-seeking response over the 'incubation of craving' period, demonstrating a strong and long-lasting disruption of METH-associated memories by myosin II inhibition.
Blebb is the only small-molecular inhibitor of nonmuscle class II myosins and was found through a small-scale screen. 70 The paucity of myosin II small-molecule inhibitors is surprising because these heavily studied molecular motors are integral to a number of cell biological processes. In addition to its efficacy in our SUD animal models, several aspects of Blebb suggest that it is an excellent starting point for medicinal chemistry efforts. Blebb is brain penetrant (Supplementary Table S3 ) and has a low molecular weight (292.3 g mol − 1 ), and a single dose is sufficient to disrupt a METH-associated memory. Further, phototoxicity reported with Blebb upon exposure to blue light was recently overcome with a C15 nitro derivative of the compound. 71 However, several aspects of Blebb are still in need of improvement from a neurotherapeutic perspective, particularly its selectivity and solubility. In addition to being an inhibitor of all three NMII isoforms (A, B and C), Blebb targets skeletal, smooth and cardiac Systemic inhibition of myosin II had no effect on (e) consolidated fear memory (Veh, n = 13; IP Blebb, n = 13) or (f) BLC spine density (Veh, n = 5; IP Blebb, n = 5) when delivered prior to testing. Error bars represent s.e.m. muscle myosin IIs, which are expressed in the adult human amygdala 72 and throughout the body. Therefore, future medicinal chemistry efforts directed at improved isoform selectivity would provide biologists with much needed NMII probes and benefit SUD neurotherapeutic discovery. 
